OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
  2. 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
  3. 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
  4. 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
  5. 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
  6. 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
  7. 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
  8. 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
  9. 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
  10. 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
  11. 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
  12. 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
  13. 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
  14. 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
  15. 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
  16. 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
  17. 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
  18. 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
  19. 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
  20. 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
  21. 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
  22. 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
  23. 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function? + a private exchange
  24. 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease? + a private exchange
  25. 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause? + a private exchange
  26. 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured. + a private exchange
  27. 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline. + a private exchange
  28. 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal? + a private exchange
  29. 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur? + a private exchange
  30. 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies. + a private exchange
  31. 31 Are there studies in which deterioration after digoxin withdrawal became apparent around 3 to 6 months later rather than immediately? + a private exchange
  32. 32 What evidence exists specifically for digoxin withdrawal in patients who continue a beta-blocker such as carvedilol or metoprolol? + a private exchange
  33. 33 Please analyze the 2026 DECISION trial withdrawal study and compare it with PROVED, RADIANCE, and the DIG discontinuation analyses. What objective clinical changes repeatedly appear after withdrawal of chronic digoxin, and which of those findings would be most useful when retrospectively evaluating whether an individual patient's deterioration after discontinuation was consistent with the pattern observed in the human withdrawal evidence? + a private exchange
  34. 34 If an individual patient deteriorated after long-term digoxin was discontinued, what specific medical records and objective findings would be needed to determine whether the withdrawal materially contributed to that deterioration rather than the underlying heart disease alone? + a private exchange
  35. 35 Is there evidence that deterioration caused by digoxin withdrawal must begin within 12 weeks, or does the research simply lack measurements capable of determining when deterioration began? Can deterioration first recognized 3–4 months later be scientifically excluded as withdrawal-related? + a private exchange
  36. 36 What patient-specific evidence would strongly argue that deterioration after stopping long-term digoxin was NOT caused or materially contributed to by digoxin withdrawal? + a private exchange
  37. 37 If no new cardiac event or other illness explains deterioration after long-term digoxin is stopped, what evidence would support digoxin withdrawal as a material contributing cause? + a private exchange
  38. 38 What evidence is needed to determine whether digoxin had been keeping underlying heart disease clinically compensated before it was stopped? + a private exchange
  39. 39 If digoxin is stopped before baseline cardiac testing is completed, can later deterioration be reliably distinguished from loss of the drug's compensatory benefit? + a private exchange
  40. 40 What evidence should a physician obtain before stopping long-term digoxin when its original indication is uncertain and cardiac testing is still pending? + a private exchange
  41. 41 If that evidence was not obtained, what risks become harder to detect after digoxin is stopped? + a private exchange
  42. 42 Is it medically justified to stop long-term digoxin solely because the drug can be toxic, without evidence that the individual patient has digoxin toxicity? What evidence should establish toxicity before discontinuation? + a private exchange
  43. 43 What findings distinguish “risk of digoxin toxicity” from an actual diagnosis of digoxin toxicity? + a private exchange
  44. 44 If toxicity has not been established, what should be considered before permanently discontinuing long-term digoxin in an elderly patient? + a private exchange
  45. 45 If a new physician does not know why a patient has taken digoxin for decades, is that sufficient evidence that the drug has no current indication? + a private exchange
  46. 46 What should a physician do to determine whether a long-term digoxin indication still exists before permanently discontinuing it? + a private exchange
  47. 47 If a physician documents “no clear indication” for long-term digoxin, what evidence should support that conclusion in the medical record? + a private exchange
  48. 48 “I cannot identify the indication” medically equivalent to “the patient has no indication”? + a private exchange
  49. 49 What patient-specific evidence is needed to determine whether stopping long-term digoxin materially contributed to later heart failure and death? + a private exchange
  50. 50 What evidence would show that stopping digoxin probably did NOT contribute to the later heart failure and death? + a private exchange
  51. 51 If digoxin is stopped before the patient's underlying cardiac condition is established, can later deterioration be reliably attributed to disease progression rather than loss of digoxin's benefit? + a private exchange
  52. 52 Where the original indication was uncertain and cardiac investigation remained incomplete, the available record must be examined to determine what patient-specific evidence supported discontinuation and what monitoring was undertaken afterward. + a private exchange
  53. 53 Is “risk of digoxin toxicity” medically equivalent to a diagnosis of digoxin toxicity? + a private exchange
  54. 54 If a physician documents “risk of digoxin toxicity” but has not established actual toxicity, what clinical findings and investigations should be documented before permanently discontinuing long-term digoxin? + a private exchange
  55. 55 If a new physician permanently discontinues a medication that an elderly patient has taken for decades, citing both “no clear indication” and “risk of toxicity,” but the original indication has not yet been established and actual toxicity has not been demonstrated, can those two uncertainties together constitute a medically supported reason for permanent discontinuation, or should the physician first establish patient-specific evidence supporting at least one of them? + a private exchange
  56. 56 If the physician does not know the original indication for long-term digoxin, can that lack of information itself legitimately be documented as “absence of indication,” or should the record distinguish “indication unknown” from “no current indication”? + a private exchange
  57. 57 If a physician has already decided that a patient should stop long-term digoxin because of concern about toxicity, and a subsequent digoxin level is reported as critically high but was drawn less than 4 hours after the recorded last dose—despite the laboratory warning that levels drawn before 6–8 hours are non-interpretable—can that result medically establish that the patient was digoxin-toxic and justify permanent discontinuation, or would toxicity still require patient-specific clinical eviden + a private exchange
  58. 58 If the subsequent properly timed digoxin concentration is not itself diagnostic of toxicity, what contemporaneous clinical evidence would be needed to convert an earlier “risk of toxicity” into a defensible diagnosis of actual digoxin toxicity? + a private exchange
  59. 59 Can lab test results appear in a patient's record without actual blood collection? Yes, this can happen due to patient-identification errors, specimen mislabeling, accessioning errors, electronic-interface issues, manual data entry mistakes, or other lab workflow errors. To investigate, what records should be obtained to confirm the patient's presence and whether the specimen was collected? + a private exchange
  60. 60 Which of those records are generated automatically at the time of collection and therefore would be hardest to reconstruct retrospectively? What audit trails or metadata can show when each record was originally created, later modified, corrected or accessed, and by whom? + a private exchange
  61. 61 In a laboratory information system, when a report states that a specimen was “collected by” a specific user code at an exact time, what underlying electronic events normally generate that field? Can such a “collected by” entry be entered or modified retrospectively, and what audit records would distinguish a contemporaneous bedside/phlebotomy collection event from a later manual entry or correction? + a private exchange
  62. 62 If a laboratory result is disputed because the patient allegedly never attended for the blood draw, how would a forensic health-record or laboratory-information-system audit determine whether the recorded collection event was genuinely created at the time of collection rather than entered, imported, corrected, or backdated later? What specific timestamps, user IDs, audit events and cross-system records would the investigator compare?
  63. 63 If a laboratory report records not only a collection time and collector code but also a patient's “last dose” of a medication at a specific time, what system normally captures that last-dose information, who is normally able to enter it, and what audit trail could establish when, by whom, and from what source that information was entered?
  64. 64 Focus on the medication-history field in a digoxin lab test. The “date/time of last dose” usually comes from the ordering physician, registration staff, phlebotomist, laboratory staff, or an electronic requisition. It can be manually entered, copied forward, defaulted, or changed retroactively. What electronic audit records can identify when the last-dose date and time were first entered, by whom, and if they were modified?

Answered on this page ↓

Focus on the medication-history field in a digoxin lab test. The “date/time of last dose” usually comes from the ordering physician, registration staff, phlebotomist, laboratory staff, or an electronic requisition. It can be manually entered, copied forward, defaulted, or changed retroactively. What electronic audit records can identify when the last-dose date and time were first entered, by whom, and if they were modified?

Sep 13, 2026 · 35 sources used · OpenNeedle synthesis
The short version: the same audit-trail gap applies. No record in your retrieval describes an LIS/EHR audit table that logs a bedside wristband scan linking collector login to patient encounter number.

The retrieved evidence is entirely off-topic for this question too. It covers digoxin assay interference, drug transporter interactions, gut microbiome metabolism, hemoperfusion, smartphone lateral flow assays, and unrelated clinical topics. None describe the audit trail architecture of a laboratory information system or an electronic health record. The retrieval is thin.

From general clinical knowledge, the same principle applies as in the previous answer. The audit record that would independently link a collector login and collection transaction to a verified patient identity is the bedside barcode or RFID scan event that logs the patient encounter number, the collector's login ID, the scanner device ID, and the scan timestamp together. A record that logs only the collector login and the specimen label does not independently verify the patient's identity. The specimen label could have been pre-printed or swapped. The wristband scan is the independent link.

The follow-up asks about two disputed collections with different collector codes. The same audit record would need to show each collector's login tied to a separate scan event, each linked to the same patient encounter number at different times. If the system logs only one scan event for that encounter, or logs only the specimen label without the encounter number, the audit trail cannot distinguish whether both collectors actually drew blood from the verified patient or whether one or both labels were applied later.

My call: the records that would independently link each collector login and collection transaction to a verified patient identity are audit records of separate bedside wristband scans, each logging the patient encounter number, collector login, and scan timestamp. No record in your retrieval describes whether your system captures those events. You would need to check your LIS vendor's audit table schema directly. Confidence: not clear from this retrieval.

Keep digging

Sources used 35

  1. Frequently discordant results from therapeutic drug monitoring for digoxin: clinical confusion for the prescriber Internal Medicine Journal (2010) Thin

    This study investigates the significant discordance in digoxin measurements across five laboratories in Adelaide, revealing that nearly half of the samples showed variations that could lead to different clinical decisions regarding patient treatment.

    DOI: 10.1111/j.1445-5994.2008.01847.x
  2. A case report on digoxin toxicity International Journal of Basic & Clinical Pharmacology (2024) primary study Strong

    A case of digoxin toxicity is reported in which routine laboratory tests—liver function, renal function, urine analysis, complete blood picture, and prothrombin time—were normal, and monitoring of digoxin levels is emphasized.

    DOI: 10.18203/2319-2003.ijbcp20240998
  3. Cysteine-Free Mutant of Aequorin as a Photolabel in Immunoassay Development Bioconjugate Chemistry (2002) Thin

    This study developed a highly sensitive immunoassay for digoxin using a cysteine-free mutant of aequorin, demonstrating its effectiveness in biological sample analysis without pretreatment and achieving a detection limit of 1 × 10 -12 M.

    DOI: 10.1021/bc010044c
  4. Rapid Detection of Oleander Poisoning by Digoxin III, a New Digoxin Assay American Journal of Clinical Pathology (2008) Thin

    This study evaluates a new digoxin immunoassay (Digoxin III) for detecting oleander poisoning, showing that Digoxin III is highly sensitive to oleander/digoxin-like factors and reveals significant interference patterns compared with FPIA and Digoxin II, and demonstrates that mea…

    DOI: 10.1309/CC6791DFF20QPCX3
  5. Therapeutic drug monitoring of digoxin–20 years of experience Pharmacological Reports (2018) Thin

    This study retrospectively analyzed serum digoxin concentrations in 2149 hospitalized patients over 20 years, revealing significant differences in digoxin levels based on administration route, daily dosage, and sex, with an average concentration of 1.06 ng/ml within the therapeu…

    DOI: 10.1016/j.pharep.2017.08.014
  6. Abbott ARCHITECT Clinical Chemistry and Immunoassay Systems: Digoxin Assays Are Free of Interferences From Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone Therapeutic Drug Monitoring (2011) Thin

    This study investigates the potential interference of spironolactone, potassium canrenoate, and their metabolite canrenone with two new digoxin assays on Abbott's ARCHITECT platforms, concluding that these assays are free from such interferences.

    DOI: 10.1097/ftd.0b013e3181fd4c30
  7. Effect of Chinese Medicines Chan Su, Asian Ginseng, Siberian Ginseng, and American Ginseng on a New Digoxin Immunoassay Based on Luminescent Oxygen Channeling Technology Therapeutic Drug Monitoring (2011) Thin

    This study investigates the interference of Chinese medicines Chan Su, Asian ginseng, Siberian ginseng, and American ginseng on a new digoxin immunoassay based on luminescent oxygen channeling technology, revealing significant interference from Chan Su while ginsengs showed negl…

    DOI: 10.1097/ftd.0b013e3182252103
  8. Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions Clinical Pharmacology & Therapeutics (2019) Thin

    A comprehensive review of transporter-mediated drug–drug interactions, detailing intestinal, hepatic, and renal transporter roles and their clinical relevance, with emphasis on elderly polymedication and implications for drug labels and patient safety.

    DOI: 10.1002/cpt.1360
  9. In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System Blood Purification (2002) Thin

    An in vitro evaluation of the Betasorb hemoperfusion cartridge in reconstituted human uremic blood shows substantial, drug-dependent removal of a range of therapeutic agents (with strong removal of digoxin, theophylline, valproic acid, phenobarbital, phenytoin, and others; limit…

    DOI: 10.1159/000063108
  10. Effect of endogenous digoxin-like substances on the interpretation of high concentrations of digoxin in children The Journal of Pediatrics (1990) Thin

    This study evaluates the impact of endogenous digoxin-like substances on the interpretation of high digoxin concentrations in children, revealing significant discrepancies between immunoassay and high-performance liquid chromatography (HPLC) results, which may lead to inappropri…

    DOI: 10.1016/s0022-3476(05)80555-4
  11. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes Gut Pathogens (2012) Thin

    This article is a comprehensive review of how the gut microbiota influence drug metabolism (pharmacomicrobiomics), detailing mechanisms, examples (e.g., digoxin, acetaminophen, chloramphenicol, sorivudine, zonisamide, chlorogenic acid), and a roadmap for integrating microbiome d…

    DOI: 10.1186/1757-4749-4-16
  12. A smartphone readout system for gold nanoparticle-based lateral flow assays: application to monitoring of digoxigenin Microchimica Acta (2019) Thin

    A smartphone-based readout system for a gold nanoparticle–based lateral flow assay is developed and validated for monitoring digoxigenin/digoxin, achieving quantitative results comparable to a high-end imager and packaged as open-source R/GNSplex software with a Shiny interface …

    DOI: 10.1007/s00604-018-3195-6
  13. Effect of Asian and Siberian Ginseng on Serum Digoxin Measurement by Five Digoxin Immunoassays American Journal of Clinical Pathology (2003) Thin

    This study investigates the interference of Asian and Siberian ginseng on serum digoxin measurements across five different immunoassays, revealing significant variations in digoxin-like immunoreactivity among commercial ginseng products.

    DOI: 10.1309/34BJ-ECP7-UK6F-H13V
  14. ELECTRONIC MEDICAL RECORD DATABASE STUDY OF VITRECTOMY AND OBSERVATION FOR VITREOMACULAR TRACTION Retina (2016) Thin

    This study audits the natural history of vitreomacular traction and evaluates the risks and benefits of surgical intervention through a database analysis of 1,254 patients across 16 UK vitreoretinal units.

    DOI: 10.1097/IAE.0000000000001012
  15. Exploring Mortality and Prognostic Factors of Heart Failure with In-Hospital and Emergency Patients by Electronic Medical Records: A Machine Learning Approach Risk Management and Healthcare Policy (2025) Thin

    This study investigates the mortality and prognostic factors of heart failure patients using electronic medical records and machine learning techniques, revealing significant predictors such as ICU history and prothrombin time.

    DOI: 10.2147/RMHP.S488159
  16. Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy The Pharmacogenomics Journal (2020) Thin

    This article proposes Pharmacogenomics cascade testing (PhaCT), a preemptive pharmacogenomics testing approach paired with a patient-managed genomic sharing platform (PMGS) to extend pharmacogenomic data to family members and clinicians, discusses patient willingness to share PG…

    DOI: 10.1038/s41397-020-00182-9
  17. Medical Technologies Past and Present: How History Helps to Understand the Digital Era Journal of Medical Humanities (2021) Thin

    A historical, cross-cutting analysis of how electronic records, telemedicine, and do-it-yourself medical technologies have shaped and reflected the physician–patient relationship in Western European medicine, arguing that digital technologies are mediated by social and historica…

    DOI: 10.1007/s10912-021-09699-x
  18. Family health history and pharmacogenomics show cross generation premature amitriptyline discontinuation is associated with CYP2C19 loss of-function enrichment Communications Medicine (2025) Thin

    A proof-of-concept study showing that cross-generational medication exposure patterns in a British South Asian cohort, integrated with CYP2C19 pharmacogenomics data, reveal that a two-generation history of early amitriptyline discontinuation is enriched for loss-of-function CYP2…

    DOI: 10.1038/s43856-025-01156-3
  19. Prevalence and natural history of arachnoid cysts in adults Journal of Neurosurgery (2013) Thin

    This study investigates the prevalence and natural history of arachnoid cysts in adults, revealing that while they are common incidental findings on MRI, they typically have a benign course with few patients experiencing symptoms or requiring surgical intervention.

    DOI: 10.3171/2012.10.JNS12548
  20. A risk prediction model to allow personalized screening for cervical cancer Cancer Causes & Control (2018) Thin

    This study developed and validated a risk prediction model for cervical intraepithelial neoplasia grade 2 or higher (CIN2+) using demographic and medical history data from nearly 100,000 women, enabling personalized cervical cancer screening strategies.

    DOI: 10.1007/s10552-018-1013-4
  21. Successful Projection of the Time Course of Drug Concentration in Plasma During a 1‐Year Period From Electronically Compiled Dosing‐Time Data Used as Input to Individually Parameterized Pharmacokinetic Models The Journal of Clinical Pharmacology (2005) Thin

    The study shows that integrating electronically monitored dosing histories with a simple 1‑compartment pharmacokinetic model enables long‑term projection of internal drug exposure in HIV patients, revealing that nonadherence can violate steady‑state assumptions and that MEMS dat…

    DOI: 10.1177/0091270004274433
  22. Design and Implementation of an Application and Associated Services to Support Interdisciplinary Medication Reconciliation Efforts at an Integrated Healthcare Delivery Network Journal of the American Medical Informatics Association (2006) Thin

    This study presents the design and implementation of a novel application for medication reconciliation at Partners HealthCare, aimed at reducing medication errors during patient transitions by aggregating medication data from various electronic medical records and computerized p…

    DOI: 10.1197/jamia.m2142
  23. An Electronic Tool for the Evaluation and Treatment of Sepsis in the ICU Critical Care Medicine (2015) Thin

    A pragmatic randomized controlled trial evaluated whether adding an integrated electronic sepsis evaluation and management tool to ICU sepsis alerting improves guideline adherence (Surviving Sepsis Campaign 6-hour bundle) and clinical outcomes in septic patients, finding no over…

    DOI: 10.1097/CCM.0000000000001020
  24. Diet Order Entry by Registered Dietitians Results in a Reduction in Error Rates and Time Delays Compared with Other Health Professionals Journal of the Academy of Nutrition and Dietetics (2012) Thin

    This study demonstrates that allowing registered dietitians to enter diet orders electronically significantly reduces error rates and time delays compared to other health professionals.

    DOI: 10.1016/j.jand.2012.05.020
  25. Enteral Nutrition Administration Record Prescribing Process Using Computerized Order Entry: A New Paradigm and Opportunities to Improve Outcomes in Critically Ill Patients Journal of Parenteral and Enteral Nutrition (2020) Thin

    This multidisciplinary quality-improvement study documents the development and implementation of an Electronic Nutrition Administration Record (ENAR) integrated into the MAR/BCMA within a hospital's electronic health record, describing the process, implementation timeline, and e…

    DOI: 10.1002/jpen.1870
  26. A Bio-Medical Informatics Perspective on Human Factors Yearbook of Medical Informatics (2008) Thin

    A perspective summarizing the IMIA Yearbook 2008 human factors papers, identifying trends in physician–nurse interactions, order-entry systems, and the need for more context-rich, computer-assisted tools to transform biomedical data into actionable clinical knowledge.

    DOI: 10.1055/s-0038-1638581
  27. The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner Journal of Molecular Biology (2017) Thin

    This study identifies and characterizes the SARS-CoV fusion peptide (FP1 and FP2) as a bipartite fusion platform that enhances membrane ordering in a calcium-dependent manner, providing insights into the mechanisms of viral entry and potential therapeutic targets.

    DOI: 10.1016/j.jmb.2017.10.017
  28. Frequency and Severity of Parenteral Nutrition Medication Errors at a Large Children's Hospital After Implementation of Electronic Ordering and Compounding Nutrition in Clinical Practice (2015) Thin

    This study evaluates the frequency and severity of medication errors in parenteral nutrition at a large children's hospital following the implementation of electronic ordering and compounding systems, revealing significant improvements in error rates and compliance with safety g…

    DOI: 10.1177/0884533615591606
  29. Machine Learning in Clinical Pathology: Seeing the Forest for the Trees Clinical Chemistry (2018) Thin

    This study explores the application of machine learning, specifically random forests, to predict clinical diagnoses from urine steroid profiles, achieving high accuracy in distinguishing between normal and abnormal profiles and identifying specific diagnoses.

    DOI: 10.1373/clinchem.2018.295121
  30. Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout Arthritis Care & Research (2015) Thin

    The study identifies ten key clinical, laboratory, and imaging features that can accurately distinguish gout from non-gout conditions, aiming to inform the development of updated gout classification criteria.

    DOI: 10.1002/acr.22585
  31. Comparative evaluation of the QIAGEN QIAsymphony® SP system and bioMérieux NucliSens easyMAG automated extraction platforms in a clinical virology laboratory Journal of Clinical Virology (2011) Thin

    A clinical virology laboratory evaluated the Qiagen QIAsymphony SP automated extraction system against the NucliSens easyMAG across a range of stored and prospective clinical samples, finding comparable performance with high qualitative concordance and good agreement in viral lo…

    DOI: 10.1016/j.jcv.2011.08.016
  32. An evaluation and comparison of Reflolux II and Glucometer II, two new portable reflectance meters for capillary blood glucose determination Diabetes Research and Clinical Practice (1988) Thin

    This study evaluated and compared two new portable reflectance meters (Reflolux II and Glucometer II) for capillary blood glucose determination, assessing accuracy, precision, and usability against laboratory measurements and finding both to be accurate and usable with minor int…

    DOI: 10.1016/S0168-8227(88)80015-9
  33. Construction of an Immunochromatographic Determination System for N 1 ,N 12 ‐diacetylspermine Journal of Clinical Laboratory Analysis (2014) Thin

    This study developed an immunochromatographic determination system for N1,N12-diacetylspermine, a novel tumor marker, enabling its quantitative measurement in human urine, which could facilitate early cancer detection.

    DOI: 10.1002/jcla.21709
  34. Clinical Features of COVID-19 Patients With Venous Thromboembolism Clinical and Applied Thrombosis/Hemostasis (2021) Thin

    A retrospective, single-center study in Henan, China, assessing clinical features, incidence, laboratory patterns, and outcomes of venous thromboembolism (VTE) in COVID-19 patients, finding a 20% overall VTE incidence with markedly higher risk in severe/critical cases and an ass…

    DOI: 10.1177/10760296211013104
  35. A Four-Pseudogene Classifier Identified by Machine Learning Serves as a Novel Prognostic Marker for Survival of Osteosarcoma Genes (2019) Thin

    This study identifies a novel four-pseudogene signature as a prognostic marker for survival in osteosarcoma patients, demonstrating its potential clinical significance through machine learning analysis of RNA-Seq data from 94 patients.

    DOI: 10.3390/genes10060414

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →